|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The HPV testing and Pap test market was valued at approximately USD 3,550 million in 2020, and it is expected to reach USD 5,180 million by 2026, registering a CAGR of 6.5% during the forecast period, 2021-2026. The driving factors of the market are the increasing number of cervical cancer cases across the globe, an increasing number of cervical cancer screening programs, and the introduction of advanced technologies.
In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize the other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening. Therefore, as the health systems will the primary care appointments, they will reopen and resume preventive care visits.
According to the World Health Organization, among women, cervical cancer is the fourth most common cancer, with an estimated 570,000 new cases in 2018, representing 6.6% of all female cancers. Approximately 90% of deaths from cervical cancer occur in the middle- to low-income countries.
Additionally, according to the American Cancer Society estimates about 13,170 new cases of invasive cervical cancer were diagnosed and about 4,250 women died from cervical cancer in the United States in 2019. Additionally, according to Cancer Australia, the number of new cases of cervical cancer diagnosed in 2019 was found to be 951 females. Thus, globally, the increasing number of cervical cancer cases may increase the demand for HPV testing and PAP tests, driving the growth of the market.
The growing number of cervical cancer cases increases the demand for screening programs. The tests are found to address deficiencies in traditional cervical screening that has led to alternative screening paradigms such as those involving detection of the human papillomavirus (HPV). Companies like Qiagen NV are having technologically advanced tests that detect HPV DNA such as Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample. Hence, all these factors have impacted the overall market growth.
Scope of the Report
As per the scope of the report, the human papillomavirus (HPV) test is used to detect the presence of the human papillomavirus, which leads to the development of genital warts, abnormal cervical cells, or cervical cancer. A Pap smear, also called Pap test or smear test, is a procedure that doctors use to find cell changes or abnormal cells in the cervix. A Pap smear removes a microscopic sample of cells from the cervix to test for cancer and precancer. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens. The HPV testing and Pap test market is segmented by test type (HPV test, Pap test, and co-testing), application (cervical cancer screening test, head and neck cancer screening test, and other applications), end user (hospitals/clinics, diagnostic centers, and point-of-care/self-sampling), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Test Type|
|Cervical Cancer Screening Test|
|Head and Neck Cancer Screening Test|
|By End User|
Key Market Trends
The Cervical Cancer Screening Test Segment is Expected to be Dominant Over the Forecast Period
Cervical cancer screening is an essential part of a woman’s routine healthcare. For women of age 30 years and above, an HPV test is recommended for detection. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.
With the rising COVID-19 burden, cervical cancer procedures and screening were found to be paused in 2020 and only the urgent procedures were being performed, which impacted the overall market growth. The cancer diagnosis was found to be delayed as screening and diagnostic services were reduced or suspended in many countries, but post-pandemic, the situation is expected to be better with the services being resumed, resulting in positive growth.
The major factor driving the growth of the segment include the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the World Health Organization, more than 270,000 women die every year due to cervical cancer.
According to the American Society of Clinical Oncology, in 2019, it was estimated that about 13,170 women in the United States will be diagnosed with invasive cervical cancer. The incidence rates for the disease dropped by more than 50% between 1975 and 2015 due in part to an increase in screening. Therefore, the incidence of cervical cancer is found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes that occur in the cervix years before cervical cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.
The cervical cancer screening tests segment is found dominating the market owing to the increasing awareness about the benefits associated with the early detection of cancer and the rising government support toward controlling cervical cancer. Hence, all these factors are expected to drive the market growth.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market Over the Forecast Period
The market in the North American region has been found dominating due to the increased number of cervical cancer cases and the growing number of screening procedures.
With the rising COVID-19 burden, HPV testing and Pap testing were found to be paused, which majorly impacted the overall market growth. There has been a dramatic impact on cervical cancer screening, which decreased by 90% as compared to the previous years. As health systems will re-open primary care appointments and resume preventive care visits, the clinic-based cervical cancer screening procedures may also gradually increase.
Cervical cancer is found to be one of the most common causes of death among women in the United States. According to the American Cancer Society, in 2020, there were around 13,800 new cases of invasive cervical cancer that were being diagnosed, and about 4,290 women died from cervical cancer. The death rate due to cervical cancer has dropped over the last 40 years, by up to more than 50%, with the increased use of testing.
There is no FDA-approved HPV test for men currently, but there are only approved tests to find HPV in a woman’s cervix. The rising number of cervical cancer cases has boosted the demand in the diagnostic HPV testing and Pap testing market.
There is one HPV test that has been recently approved (Cobas test) for use as primary cervical cancer screening for women aged 25 years and older, followed by a Pap test for women with certain results. There are also many new tests in development that can improve the evaluation of HPV-positive women. Thus, due to the increasing demand for Pap, HPV, and other tests for cancer screening, the market is expected to grow.
Additionally, favorable government policies in North America are expected to drive the overall market during the forecast period. In the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening has helped in driving the overall market growth.
To understand geography trends, Download Sample Report
Some of the major players in the HPV test and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, and many others. These key players are found focusing on inorganic and organic strategies such as product approvals and licenses, agreements, collaborations, partnerships, expansions, and acquisitions to sustain their growth in the HPV testing and Pap test market. Also, receiving approvals from regulatory authorities for new product launches will render the companies with a competitive advantage.
In April 2020, Roche has announced the US Food and Drug Administration (FDA) approval for the Cobas HPV test for use on the fully automated, high-throughput Cobas 6800/8800 Systems.
In January 2020, Qiagen NV collaborated with Amgen Inc. to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cervical Cancer Cases
4.2.2 Increasing Number of Cervical Cancer Screening Programs
4.2.3 Introduction to Advanced Technologies
4.3 Market Restraints
4.3.1 HPV Vaccination
4.3.2 Changes in Regulatory Guidelines for Cervical Cancer Screening
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test Type
5.1.1 HPV Test
5.1.2 Pap Test
5.2 By Application
5.2.1 Cervical Cancer Screening Test
5.2.2 Head and Neck Cancer Screening Test
5.2.3 Other Applications
5.3 By End User
5.3.2 Diagnostic Centers
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Arbor Vita Corporation
6.1.2 Danaher Corporation (Cepheid)
6.1.3 Seegene Inc.
6.1.4 Becton, Dickinson and Company
6.1.6 Abbott Laboratories
6.1.7 Hologic Inc.
6.1.8 Qiagen NV
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Quest Diagnostics
6.1.11 OncoHealth Corporation
6.1.12 Netdox Health Pvt. Ltd
6.1.13 Femasys Inc.
6.1.14 Cepheid Inc.
6.1.15 Takara Bio Inc.
6.1.16 DiagCor Bioscience Inc. Ltd
6.1.17 Fujirebio Diagnostics Inc.
6.1.18 Zytovision GmbH
6.1.19 Medical & Biological Laboratories Co. Ltd
6.1.20 Promega Corporation
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global HPV Testing and Pap Test Market market is studied from 2018 - 2026.
What is the growth rate of Global HPV Testing and Pap Test Market?
The Global HPV Testing and Pap Test Market is growing at a CAGR of 6.5% over the next 5 years.
What is Global HPV Testing and Pap Test Market size in 2018?
The Global HPV Testing and Pap Test Market is valued at 3550 Million USD in 2018.
What is Global HPV Testing and Pap Test Market size in 2026?
The Global HPV Testing and Pap Test Market is valued at 5180 Million USD in 2026.
Which region has highest growth rate in Global HPV Testing and Pap Test Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global HPV Testing and Pap Test Market?
North America holds highest share in 2020.
Who are the key players in Global HPV Testing and Pap Test Market?
Arbor Vita Corporation, Qiagen NV, F. Hoffmann-La Roche Ltd, Seegene Inc., Becton, Dickinson and Company are the major companies operating in Global HPV Testing and Pap Test Market.